Dr. Smith is a behavioral pharmacologist and a co-investigator in the NIH-sponsored Anticonvulsant Drug Development (ADD) Program, where she provide leadership and expertise in all of the preclinical models of acute and chronic seizure activity as well as in the assessment of behavioral comorbidities associated with epilepsy. Dr. Smith coordinates the management of all regulatory and safety standards and licenses necessary to preserve the ADD Program’s high standards of scientific rigor and excellence in research. In hopes of better understanding the comorbidities of epilepsy and their underlying mechanisms, Dr. Smith’s evaluates the therapeutic potential of investigational compounds in both acute and chronic preclinical models of seizures, epilepsy and the neuropsychiatric comorbidities of epilepsy. Dr. Smith’s current research is aimed at the evaluation of the interactions of cannabidiol with various classes of antiseizure drugs utilizing isobolographic and pharmacokinetic analyses. This research will not only help provide information on the efficacy and safety of unique antiseizure drugs (ASDs), such as cannabidiol, both alone and in combinations with other ASDs utilized in patients with epilepsy. The identification of novel compounds with broad or unique spectrums of therapeutic activity may help to better clarify the etiology of the epilepsy and its comorbidities and the most effective targets for their treatment. Furthermore, understanding the nature of drug interactions will help identify better and safer drug combinations for the patient with epilepsy. Additional related research interests include the role of neuropeptides, steroid hormones, and sex differences in neurological conditions and their pharmacological treatment.